Table 1 Patient demographics and baseline characteristics

	PX-866 dose cohort
Demographic or patient characteristic	4 mg ( N= 10)	6 mg ( N= 10)	8 mg ( N= 23)	Total ( N= 43)(%)
Age, median (years)	62	57	57	59
ECOG PS^a=0	3	0	6	9
ECOG PS^a^b=1	7	10	16	33
Male	4	4	12	20 (47)
Female	6	6	11	23 (53)
White or Caucasian	9	10	21	40 (93)
Black of African American	1	0	1	2 (5)
Hispanic	0	0	1	1 (2)
Number of prior treatments	2.5 (range: 1–8)	3 (range: 1–11)	2 (range: 1–11)	2 (range: 1–11)
Number of patients with tumour type
SCCHN	3	1	2	6 (14)
Ovarian	2	1	2	5 (12)
Prostate	0	1	4	5 (12)
NSCLC	1	1^c	3	5 (12)
Other^d	4	6	12	22 (51)

Abbreviations: ECOG=Eastern Cooperative Oncology Group; NSCLC=non-small cell lung cancer; PS=performance status; SCCHN=squamous cell carcinoma of the head and neck.
^aECOG PS was not available for one patient.
^bOne patient was an ECOG PS of 1 at screening but was an ECOG PS of 2 at the time of the first dose.
^cOne patient was enrolled but did not receive study treatment.
^dSmall cell lung (N=2); adenoid cystic (N=2); bladder (N=2); pancreatic adenocarcinoma (N=2); endometrial (N=2); neurogenic lung (N=1); pancreatic neuroendocrine (N=1); melanoma (N=1); cervical (N=1); breast (N=1); Merkel Cell (N=1); gastroesophageal (N=1); ureter (N=1); rectal (N=1); nasopharyngeal (N=1); anal (N=1); and gastric (N=1).

Quick links

Search